Frank Papay, MD

Frank Papay, MD, is the Chairman of the Dermatology & Plastic Surgery Institute at Cleveland Clinic. Dr. Papay has been a member of Cleveland Clinic's professional staff since 1992. He also serves as Section Head of Craniofacial Plastic and Reconstructive Surgery. He is a Professor of Surgery in Cleveland Clinic's Lerner College of Medicine at Case Western Reserve University.

Dr. Papay has been recognized as a Top Doc in plastic surgery by Cleveland magazine and Castle Connolly. Dr. Papay has served as President of the Ohio Valley Society of Plastic Surgeons, elected Chair of the American Society of Plastic Surgery's Ethics Committee, President of the Plastic Surgery Section of the American Academy of Pediatrics and Executive Committee Member of the Academy of Medicine of Cleveland and Northern Ohio.

Dr. Papay has published over 100 scientific papers, abstracts and book chapters and holds five medical device patents. He has served as the Board Examiner of the American Board of Plastic Surgery, Finalist Judge for the collegiate inventors' competition from the National Inventors Hall of Fame and invited section reviewer of several plastic surgery scientific journals.

Michael Vogelbaum, MD, PhD

Michael A. Vogelbaum, MD, PhD, is Program Leader of NeuroOncology and Chief of Neurosurgery at Moffitt Cancer Center.  He is also Professor of Oncological Sciences at the University of South Florida Morsani Medical School. He received his MD and PhD (Biomedical Engineering) from University of Virginia and completed his residency in neurosurgery at Barnes Hospital/Washington University in St. Louis.  He spent nearly 20 years at the Cleveland Clinic where he was Associate Director of the Rose Ella Burkhardt Brain Tumor and NeuroOncology Center and held the Kathryn and Robert Lamborn Chair for NeuroOncology.

In addition to his active neurosurgery and radiosurgery practice, Dr. Vogelbaum has been Primary Investigator of numerous local and national clinical trials of new drugs and surgical techniques and devices for brain tumors.  He has an externally funded (including NIH R01 funded) basic science and translational research program which currently focuses on immunobiology of brain tumors, and various aspects of drug delivery to brain tumors including both Phase 0/Window of Opportunity clinical trials, and trials that involve active delivery of therapeutic agents to the brain.  He is currently developing novel devices for delivering therapeutics directly to the brain, for which he has received multiple patents.  The first of these devices has been used in clinical trials and it has received a 510(k) clearance from the FDA.  He is the co-Founder and Chief Medical Officer of Infuseon Therapeutics, Inc., a company that was spun-off from the Cleveland Clinic to commercialize his therapeutic delivery devices.

Dr. Vogelbaum is a founder of the RANO (Response Assessment in NeuroOncology) group, Chair of the Neurosurgery Committee for NRG Oncology, and he has been a Vice President of the Society for NeuroOncology (SNO). He is a member of the editorial board for The Journal of Neurosurgery and the journals Neuro-Oncology and Neurosurgery, Tumor Section co-Editor of World Neurosurgery and he is co-Editor of the comprehensive textbook of neuro-oncology, Principles and Practice of Neuro-Oncology (2011).

Rishi Singh, MD

Dr. Rishi P. Singh MD is a staff surgeon at the Cole Eye Institute, Cleveland Clinic and Professor of Ophthalmology at the Lerner College of Medicine in Cleveland Ohio. He also currently serves as the medical director of informatics at the Cleveland Clinic. He received his bachelors and medical degrees from Boston University and completed his residency at the Massachusetts Eye and Infirmary Harvard Combined Program in Boston, Massachusetts. Dr. Singh then completed a medical and surgical fellowship at the Cole Eye Institute in Cleveland, Ohio. 

He specializes in the treatment of medical and surgical retinal disease such as diabetic retinopathy, retinal detachment, and age-related macular degeneration. Dr. Singh has authored more than 200 peer reviewed publications, books, and book chapters and serves as the principal investigator of numerous national clinical trials advancing the treatment of retinal disease. Dr. Singh is the former president on the Retina World Congress and is on the board of the American Society of Retina Specialists.  

Dr. Singh has been honored with several research recognitions such as the Alpha Omega Alpha Research Award and American Society of Retina Specialists Senior Honor Award.

Amresh Raina, MD

Dr. Raina, MD, is a nationally renowned physician with expertise in the diagnostic evaluation and management of pulmonary hypertension. His current role is Associate Medical Director of the Pulmonary Hypertension Program at Allegheny Health Network. He has published extensively in this field with numerous peer-reviewed manuscripts, abstracts and book chapters. Dr. Raina was named one of Pittsburgh Magazine's "Best Doctors" in 2019.

He received his medical degree from Columbia University College of Physicians and Surgeons and completed his residency at New York Presbyterian Hospital. Dr. Raina then completed fellowships at New York Presbyterian Hospital and University of Pennsylvania Health System.

Bela Anand-Apte, MD, PhD, MBA

Dr. Anand-Apte is the Chairman of Ophthalmic Research at the Cole Eye Institute at the Cleveland Clinic Foundation. She is also Professor of Ophthalmology and Molecular Medicine at the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. She joined the Cleveland Clinic in 1996. 

Her research team explores the basic biological mechanisms of vision loss due to abnormal growth of blood vessels in the eye with special emphasis on Sorsby fundus dystrophy, age- related macular degeneration and diabetic retinopathy. Dr Anand-Apte received the equivalent of an MD degree from King Edward Memorial Hospital and Bombay University in India. Having developed an interest in research she completed a Ph.D. degree in Immunology and Microbiology from the Boston University School of Medicine in Boston, Massachusetts. A brief postdoctoral fellowship in the Department of Cell and Developmental Biology at Harvard University was followed by a Research Associate position at Children’s hospital in Boston in the Department of Surgical Research. 

She has received the Karen Grunebaum award for research in Cancer, the Tom and Sandy Trudell Research Award for the study of retinal degenerative diseases, awarded through the Foundation Fighting Blindness and the Lew Wasserman Award from RPB (Research to Prevent Blindness). Research from her laboratory has led to the understanding of novel functions for matrix metalloproteinases and their inhibitors in neovascularization and its implications in inherited retinal dystrophies and age-related macular degeneration. A more recent focus on regulation of the blood retinal barrier in diabetic retinopathy is providing interesting insights into the loss of vision in diabetes. The ultimate goal is an improved understanding of ocular pathologies that lead to blindness. Dr. Anand-Apte has a strong commitment to improving diversity in the biomedical science research field and has played a pivotal role in establishing programs at the Cleveland Clinic to reach this goal.

Ali Khademhosseini, phd

Ali Khademhosseini is the CEO of the Terasaki Institute for Biomedical Innovation. Formerly, he was Levi Knight Professor of Bioengineering, Chemical Engineering, and Radiology at the University of California-Los Angeles (UCLA). He was the Founding Director of the Center for Minimally Invasive Therapeutics at UCLA. 

He joined UCLA starting from Nov. 2017 from Harvard University where he was a Professor at Harvard Medical School (HMS) and faculty at the Harvard-MIT’s Division of Health Sciences and Technology (HST), Brigham and Women’s Hospital (BWH) as well as an associate faculty at the Wyss Institute for Biologically Inspired Engineering. At Harvard University, he directed the Biomaterials Innovation Research Center (BIRC) a leading initiative in making engineered biomedical materials.  

He is a leader in applying bioengineering solutions to precision medicine. His large and interdisciplinary group is interested in developing ‘personalized’ solutions that utilize micro- and nanoscale technologies to enable a range of therapies for organ failure, cardiovascular disease, and cancer. In enabling this vision, he works closely with clinicians (including interventional radiologists, cardiologists, and surgeons). For example, he has developed numerous techniques in controlling the behavior of patient-derived cells to engineer artificial tissues and cell-based therapies. He is also developing ‘organ-on-a-chip’ systems that aim to mimic human physiology and pathology to enable patient-specific evaluation of drug candidates. In addition, his laboratory is a leader in utilizing biofabrication to form vascularized tissues with appropriate microarchitectures as well as regulating stem cell differentiation in microengineered environments. He has also pioneered various high-performance biomaterials that can respond to each patient’s needs. He has edited multiple books/journal special issues and is an author on >650 peer-reviewed journal articles, editorials and review papers, >70 book chapters/edited books, and >20 patent/disclosure applications. His work has been published in leading journals and routinely highlighted in international media.  He has been cited >73,300 times and has an H-index of 139. Also, he has given over 250 invited seminars and keynote lectures. Annually for the past five years, he has been selected by Thomson Reuters as one of the World’s Most Influential Minds as a Highly Cited Researcher.

Dr. Khademhosseini’s interdisciplinary research has been recognized by over 60 major national and international awards. He is the recipient of the Presidential Early Career Award for Scientists and Engineers (PECASE), the highest honor given by the US government for early-career investigators. In 2007, he was named a TR35 recipient by the Technology Review Magazine as one of the world’s top young innovators. In 2011, he received the Pioneers of Miniaturization Prize from the Royal Society of Chemistry (RSC) for his contribution to microscale tissue engineering and microfluidics.  In 2016, he received the Sr. Scientist Award of Tissue Engineering and Regenerative Medicine Society-Americas (TERMIS-AM) and in 2017 he received the Clemson Award of the Society for Biomaterials. He is a fellow of the American Institute of Medical and Biological Engineering (AIMBE), Biomedical Engineering Society (BMES), Royal Society of Chemistry (RSC), Biomaterials Science and Engineering (FBSE), Materials Research Society (MRS), NANOSMAT Society, and American Association for the Advancement of Science (AAAS). He is also the recipient of the Mustafa Prize ($500,000 prize) as well as a member of the International Academy of Medical and Biological Engineering, Royal Society of Canada, and Canadian Academy of Engineering.

Dr. Khademhosseini is highly interested in training students and postdoctoral fellows for which he received the MIT’s Outstanding Undergraduate mentor. Over 50 of his previous trainees have gone to academia as faculty at institutions including Harvard University-Massachusetts General Hospital, Brigham and Women’s Hospital, University of California-Riverside, Arizona State University, Texas A&M University, University of Pittsburgh, INSERM, Northeastern University, Hanyang University, Singapore National University, and Tsinghua University.

Dr. Khademhosseini is an Associate Editor for ACS Nano. Previously, he served as the Research Highlights editor for Lab on a Chip. He is on the editorial boards of numerous journals including Small, RSC Advances, Advanced Healthcare Materials, Biomaterials Science, Journal of Tissue Engineering and Regenerative Medicine, Biomacromolecules, Reviews on Biomedical Engineering, Biomedical Materials, Journal of Biomaterials Science-Polymer Edition and Biofabrication. He received his Ph.D. in bioengineering from MIT (2005), and MASc (2001) and BASc (1999) degrees from the University of Toronto both in chemical engineering.

Charles Martin, md

Dr. Charles “Chuck” Martin is a Vascular and Interventional Radiologist on staff at The Cleveland Clinic where he currently serves as the Director of the Interventional Oncology subgroup and the IR liaison to the Clinic’s HHT Center of Excellence. He is an Assistant Professor at The Cleveland Clinic Lerner College of Medicine. In addition, Dr. Martin is involved in educational activities with the Diagnostic and Interventional Radiology residents, the medical students of the CCF Lerner College of Medicine, as well as his clinical colleagues. Dr. Martin has been recognized as a “Top Doc” in Vascular and Interventional Radiology by Cleveland Magazine and Castle Connolly and serves as a Board Examiner for the American Board of Radiology.

He completed his undergraduate studies at The Johns Hopkins University and medical school at Case Western Reserve University. After completing his Diagnostic Radiology residency at University Hospitals Case Medical Center, he obtained subspecialty fellowship training in Vascular and Interventional Radiology at Yale University/Yale New Haven Hospital. He also serves as Chair of the Medical Advisory Board of MediView, LLC, as well as the Principal Investigator of their clinical studies and leads their clinical initiatives and implementation of their technology. Chuck is currently enrolled in the Executive MBA program at the Case Western Reserve University Weatherhead School of Management and is expected to receive his degree in May 2022.

His research interests include Hereditary Hemorrhagic Telangiectasia (Osler-Weber-Rendu) and its manifestations, Interventional Oncology, embolotherapy, medical device development, Augmented and Virtual Reality, mobile health technology, and educational strategies for medical students and residents.

He has lectured and presented his work around the country on these and other topics. Chuck serves on numerous committees throughout organized medicine including the American College of Radiology, the Society of Interventional Radiology, the National Medical Association, the Cleveland Medical Association, and the Ohio Radiologic Society.  

Outside of the hospital, Dr. Martin is an avid reader of nonfiction, and most enjoys spending time with his family – wife Kimberly and their three young children. 

Tim Raderstorf, phd

Dr. Tim Raderstorf is an author, educator, and thought leader in the field of Healthcare Innovation. From TED talks to textbooks, Tim uses every platform he can find to empower those at the frontlines to change healthcare. As the first nurse to have held the Chief Innovation Officer title in academia, he takes pride in educating the world on the role of the nurse as an innovator.

He was the founder of the Innovation Studio, a makerspace that democratizes innovation, providing every interprofessional team that pitches their innovation with the funding, tools, and mentorship needed to turn ideas into actions. Throughout his career, Tim has founded multiple businesses and has been the first employee for a profitable healthcare startup. His new textbook co-authored with Bern Melnyk, Evidence-Based Leadership, Innovation and Entrepreneurship in Nursing and Healthcare: A Practical Guide for Success, was a #1 new release on Amazon and the American Journal of Nursing’s Management & Leadership Book of the Year.

Some of Tim’s recognitions include the Early Career Innovator of the Year and Distinguished Recent Alumni at the Ohio State University, the Innovation Studio being named Non-Profit of the year by Columbus Business First in 2019, and he was most recently inducted into the 2020 Class of 40 under 40 by Columbus Business First and as a 2021 Fellow at the American Academy of Nursing.